Table 3.

Treatment costs according to two different hypothetical treatments (scenarios 2 and 3). Scenario 2: hypothetical treatment scenario with native E. coli asparaginase used as first-line treatment; and switch to Erwinia asparaginase as second-line treatment after allergy to native E.coli asparaginase. Scenario 3: hypothetical treatment scenario with native E. coli asparaginase used as first-line treatment; PEGasparaginase used as second-line after native E.coli asparaginase allergy; and switch to Erwinia asparaginase as third-line treatment after PEGasparaginase allergy.

Table 3.